OSE Immunotherapeutics is an integrated biotechnology company focused on inflammatory disease and cancer treatment.
OSE Immunotherapeutics has raised $1.5M in total funding. The most recent round was Grant. The last funding was announced in May 2025.
OSE Immunotherapeutics's investors include European Investment Bank, Bpifrance, France 2030, Government of France, Pays de la Loire region.
OSE Immunotherapeutics is headquartered in Nantes, France.
OSE Immunotherapeutics is an integrated biotechnology company focused on inflammatory disease and cancer treatment.
OSE Immunotherapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OSE Immunotherapeutics — Funding & Investors." VCBacked, May 21, 2025, https://www.vcbacked.co/company/ose-immunotherapeutics. Accessed July 26, 2026.
VCBacked. (2025). OSE Immunotherapeutics — Funding & Investors. Retrieved July 26, 2026, from https://www.vcbacked.co/company/ose-immunotherapeutics
{{cite web |title=OSE Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ose-immunotherapeutics |website=VCBacked |access-date=July 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated